Abstract. Hypercalciuria is the major risk factor promoting stone formation in Dent's disease, also known as X-linked recessive nephrolithiasis, but the effects of diuretics on calcium excretion and other stone risk factors in this disease are unknown. This study examined urine composition in eight male patients with Dent's disease, ages 6 to 49 yr, all of whom were hypercalciuric and had inactivating mutations of CLCN5. Eight males, ages 7 to 34 yr, with idiopathic hypercalciuria (IH) served as controls. Patients were instructed to maintain a consistent intake of sodium, potassium, calcium, and protein.
calcium excretion significantly in either patient group. With chlorthalidone, calcium excretion fell to normal (Ͻ4.0 mg/kg per d) in all but one patient in each group. Amiloride alone had no significant effect on urinary calcium excretion, in either patient group. In patients with Dent's disease during chlorthalidone therapy, the supersaturation ratios for calcium oxalate and calcium phosphate fell by 25% and 35%, respectively. Mean citrate excretion was reduced by chlorthalidone (P Ͻ .04) and by chlorthalidone in combination with amiloride (P Ͻ .02). There were no significant differences in the responses to these diuretics between the patient groups in any of the urinary parameters. The intact hypocalciuric response to a thiazide diuretic indicates that inactivation of the ClC-5 chloride channel does not impair calcium transport in the distal convoluted tubule and indicates that thiazides should be useful in reducing the risk of kidney stone recurrence in patients with Dent's disease.
Dent's disease, also known as X-linked recessive nephrolithiasis, is an hereditary condition characterized by hypercalciuria, nephrocalcinosis, kidney stones, proteinuria, progressive renal failure, and, in some patients, rickets. It is associated with mutations that inactivate the voltage-gated chloride channel ClC-5 (1) (2) (3) (4) (5) . This channel is expressed in intracellular membranes of the cortical proximal tubule, medullary thick ascending limb, and ␣-intercalated cells of the human nephron (6) .
Nephrocalcinosis occurs in 75% and kidney stones in 50% of affected males with Dent's disease (5,7). The major risk factor promoting stone formation in this disease is hypercalciuria, which is present in most affected males until the onset of renal insufficiency. Calcium excretion can exceed 10 to 12 mg/kg per day in young boys, but the range of calcium excretion in teenage and adult males with Dent's disease (4 to 6 mg/kg per day) is similar to that seen in patients with idiopathic hypercalciuria (IH). Urinary excretion of oxalate, citrate, and uric acid is usually normal. Oral calcium loading in hypercalciuric patients with Dent's disease reveals an exaggerated postabsorptive rise in urinary calcium excretion; some of these (particularly children) have fasting hypercalciuria as well. This occurs in the setting of suppressed serum levels of parathyroid hormone and often elevated levels of 1,25-dihydroxyvitamin D (5, 8) . This pattern of calcium handling is also found in many patients with IH.
Therapies to reduce stone risk in Dent's disease have not been evaluated formally. Thiazide diuretics have been shown to be effective in correcting hypercalciuria and reducing the rate of stone recurrence in patients with IH (9 -11). However, thiazides promote hypokalemia, which can lower urinary citrate excretion. Citrate reduces stone risk by lowering ionized calcium in the urine and inhibiting crystallization of calcium oxalate (12) . Hypokalemia occurs spontaneously in about one third of patients with Dent's disease (5, 7) . Amiloride also increases distal tubular calcium reabsorption and has been used as a therapy for idiopathic hypercalciuria. Although amiloride alone appears to be less effective than thiazide in reducing calcium excretion, amiloride may potentiate the beneficial effect of thiazides on hypercalciuria and reduce the risk of hypokalemia and alkalosis (13, 14) .
We studied the effects of thiazide, amiloride, and the combination, on the urinary stone risk profile in patients with Dent's disease and in a similar group of patients with IH.
Materials and Methods

Subjects
We studied eight male patients with Dent's disease and eight male patients with IH. Baseline data on these individuals are given in Table 1 . The diagnosis of Dent's disease was based on the presence of lowmolecular weight proteinuria, hypercalciuria, and microscopic hematuria in a patient with a documented mutation in the CLCN5 gene. We excluded patients whose GFR (measured by clearance of creatinine or iothalamate) was below 80% of the mean of normal for age. Patients with IH were found to be hypercalciuric on evaluation for kidney stones. All subjects were documented to have hypercalciuria (Ͼ300 mg/d or Ͼ4 mg/kg per d) on multiple 24-h urine collections while ingesting a random diet. All patients had normal serum calcium levels. Subjects were excluded if they had any other condition that could cause hypercalciuria such as hyperparathyroidism, inflammatory disease, cancer, thyrotoxicosis, Paget disease, Addison disease, or other such conditions. Patients were excluded if they had any contraindication to therapy with either chlorthalidone or amiloride, such as a prior untoward reaction or allergy to these drugs. Any diuretics were discontinued, and no subject was taking any medications other than as specified in the protocol during the 10 wk of the study. The study was approved by the Institutional Review Board for the Protection of Human Subjects of the Upstate Medical University, as well as those of the other participating institutions, and informed consent was obtained.
Study Protocol
Patients were instructed to follow a diet containing a moderate amount of sodium (2 to 4 g) and calcium (800 mg) similar to that used in our previous study of calcium excretion in X-linked nephrolithiasis (8) . After a baseline evaluation consisting of a review of available data regarding eligibility (see Inclusion Criteria), a medical examination, and measurement of serum electrolytes and calcium levels, patients were observed through a baseline period of 2 wk on no treatment followed by three treatment phases of 2 wk each in which they received 25 mg of chlorthalidone daily, 5 mg of amiloride daily, and the combination of 25 mg of chlorthalidone plus 5 mg of amiloride daily. Diuretic doses were reduced by 50% in boys Յ11 yr old. Patients were randomized at entry to receive one of six potential protocols with different sequences for these three treatment periods. At the end of the baseline period and each treatment period, two successive 24-h urine collections were obtained. Treatment periods were separated by a 1-wk washout period off diuretics ( Figure 1 ).
Twenty-four-hour urine specimens were analyzed for a complete stone panel, which includes measurement of calcium, phosphorus, oxalate, citrate, sodium, potassium, magnesium, uric acid, pH, ammonium, creatinine, and other measures, as well as calculation of a Baseline characteristics of study subjects. GFR was measured by creatinine clearance except in one patient (*) in whom it was measured by iothalamate clearance. In each patient with Dent's disease, a mutation in CLCN5 was reported in the cited reference. IH, idiopathic hypercalciuria; S cr , serum creatinine; Ca excr , calcium excretion. supersaturation ratios for calcium oxalate, calcium phosphate, and uric acid. These measurements were made at the Kidney Stone Research Laboratory at the University of Chicago (15) . Values for a given 24-h collection were excluded from analysis if the creatinine excretion on that collection varied by more than 15% or the sodium excretion varied by more than 25% from the mean of values for other collections by that patient; these criteria were specified in advance of the study. Of the 128 duplicate 24-h urine collections obtained from the 16 patients included in four phases of this study, 14 were discounted because they failed to meet these criteria. In each case, a duplicate specimen was available.
One patient with Dent's disease discontinued the study because of inability to tolerate diuretic therapy, and another patient with Dent's disease was excluded from the study because urinary creatinine and sodium values revealed that he had failed to follow instructions throughout the study. The data shown represent the remaining eight patients with Dent's disease.
Compliance with dietary instructions was also monitored through dietary questionnaires administered at the end of each study period. Dietary content of sodium, calcium, calories, and protein were estimated from the responses to these questionnaires, and intake was analyzed by ANOVA as described below. There were no significant differences in these measures between patient groups or across treatment periods.
Statistical Analyses
Patients served as their own control for this study, using the initial period of observation on the study diet alone as a baseline. Treatment, therefore, represents a repeated-measures factor in our experimental design. Each data point for analysis represents the subjects' mean of measurements made on duplicate 24-h urine collections, except when one of the duplicates was excluded by virtue of the criteria described above.
The data were submitted to a two-factor, mixed-model ANOVA, setting ␣ ϭ 0.05. Our design crossed four within-subjects treatments (baseline, chlorthalidone, amiloride, and chlorthalidone plus amiloride) with two between-subjects conditions (Dent's disease and IH). This design enabled us to examine overall treatment effects regardless of condition, overall condition effects regardless of treatment, and the potential for an interaction of condition and treatment whereby patterns of responses to the three treatments (relative to control) were different in patients with IH and Dent's disease. Because we were specifically interested in evaluating chlorthalidone, amiloride, and the combination of both diuretics in comparison with baseline measures, we also included a priori contrasts in the analysis comparing each levels of treatment to baseline control.
Results
Baseline Measurements
Data obtained from the baseline period, on the study diet and without diuretics, are summarized in Table 2 . Using an independent measures t test, the only significant differences between the patients with Dent's disease and those with IH in any of these measures during the baseline period was in urine pH and uric acid supersaturation. Urine pH was significantly higher in patients with Dent's disease than in those with IH (P Ͻ 0.03), and supersaturation for uric acid was consequently lower (P Ͻ 0.03). There was no difference between the two groups in uric acid excretion.
Urinary supersaturation for calcium oxalate was significantly higher in the patients with IH (P ϭ 0.05; Table 2 ), reflecting small differences in urinary oxalate, citrate, and volume that individually were NS. Two patients with Dent's disease (patients 6 and 8) and three patients with IH (patients 12, 13, and 16) were hyperoxaluric. Patient 9 (with IH) but none of the patients with Dent's disease had hypocitraturia at baseline.
Effects of Treatment on Calcium Excretion
The analysis revealed a significant main effect for treatment on calcium excretion, no significant effects for group, and no interaction effect. A priori contrasts comparing each drug intervention to baseline revealed a significant lowering of calcium excretion (mg/kg per 24 h) relative to baseline after treatment with chlorthalidone alone both for patients with Dent's disease and those with IH (P Ͻ 0.002). With chlorthalidone, calcium excretion fell to normal (Ͻ4.0 mg/kg per 24 h) in all but one patient in each group. However, the a priori contrasts revealed no change in calcium excretion with amiloride alone relative to baseline. With the combination of amiloride plus chlorthalidone (P Ͻ 0.003), the reduction in calcium excretion was similar to that with chlorthalidone alone.
These results were consistent for calcium excretion expressed as mg/kg per 24 h, mg/24 h, or mg/g creatinine. Compared with the baseline period, calcium excretion was significantly reduced during treatment with chlorthalidone in patients with Dent's disease or IH whether expressed as mg/kg per 24 h, mg/24 h, or mg/g creatinine (P Ͻ 0.003, P Ͻ 0.001, P Ͻ 0.002, respectively). Similarly, chlorthalidone plus amiloride reduced calcium excretion relative to baseline by any of the three measures, regardless of patient group (P Ͻ 0.002, P Ͻ 0.004, P Ͻ 0.004, respectively). Amiloride alone had no effect on calcium excretion relative to baseline by any of the three measures. Figure 2 illustrates the results expressed as mg/kg per 24 h.
Effects of Treatment on Supersaturation Ratios
The a priori contrasts comparing mean supersaturation ratios for calcium oxalate with each treatment relative to baseline showed a reduction when treated with chlorthalidone alone or in combination with amiloride, but the reduction reached traditional levels of statistical significance for the combination treatment only ( Figure 3A , P Ͻ 0.02). This effect was similar in patients with Dent's disease and IH. Mean supersaturation ratios for calcium phosphate in patients with Dent's disease were lower during treatment with chlorthalidone (1.56 Ϯ 0.17) than at baseline (2.40 Ϯ 0.29), but this did not reach statistical significance ( Figure 3B , P ϭ 0.074).
The analysis of supersaturation ratio for uric acid revealed a significant a priori interaction contrast comparing the response to chlorthalidone relative to baseline for patients with IH and Dent's disease (P Ͻ 0.03). Patients with IH showed a more dramatic decrease in their supersaturation ratios for uric acid than those with Dent's disease during treatment with chlorthalidone. All of the supersaturation ratios for uric acid are well below the upper limit of normal (1.0); therefore these patients are not at risk for uric acid stones.
Other Effects on Urine Composition
Some comparisons revealed statistically significant effects of treatment on excretion of citrate and uric acid, and these data are shown on Table 3 . There was a significant decline in mean citrate excretion relative to baseline, regardless of patient group, with chlorthalidone alone, (P Ͻ 0.039). Contrary to expectations, the addition of amiloride to chlorthalidone was also associated with a significant decline in mean citrate excretion (P Ͻ 0.02). Mean uric acid excretion was somewhat lower than baseline with all treatment periods, but this was only significant for treatment with amiloride (P Ͻ 0.03). Mean excretion of phosphate was generally lower during treatment periods than at baseline, but the difference was only significant for treatment with chlorthalidone (P Ͻ 0.02). There were no differences in oxalate excretion with any of the treatment periods, nor were there differences between patients with Dent's disease and IH in oxalate excretion. Twenty-four-hour urinary pH was significantly higher at baseline in patients with Dent's disease than in those with IH (Table 2 ; P Ͻ 0.03). Urine pH rose significantly during treatment with chlorthalidone alone (P Ͻ 0.01) and chlorthalidone plus amiloride (P Ͻ 0.05) regardless of patient group (Table 3) . It is possible that this reflects an effect of the thiazide to inhibit carbonic anhydrase (19) or perhaps an effect of hypokalemia (if it occurred) to suppress aldosterone production and thereby reduce the stimulation by aldosterone of the H ϩ -ATPase in the collecting duct (20) .
Analysis of urine volume revealed a main effect for condition, with urine volumes consistently higher in the patients with Dent's disease (P Ͻ 0.03). This is consistent with the common observation of a urinary concentrating defect in Dent's disease (5, 8, 17) . There were no significant differences in urinary ammonium excretion.
Discussion
At baseline on a controlled diet, patients with Dent's disease had degrees of hypercalciuria comparable to those with IH. Anecdotal reports had indicated that urinary excretion of citrate is normal in patients with Dent's disease and that excretion of oxalate is usually normal (8, 16, 17) . Our baseline measurements indicate that excretion of citrate and oxalate were similar in Dent's disease and IH, that hyperoxaluria was seen no more frequently in the patients with Dent's disease than in those with IH, and that none of the patients with Dent's disease was hypocitraturic. Occasional cases of hyperuricosuria have been reported in Dent's disease (16, 17) , though hypouricemia has not been described. In this study, urinary excretion of uric acid in patients with Dent's disease was very similar to that in patients with IH.
The significantly lower supersaturation ratio for uric acid in patients with Dent's disease at baseline was accounted for by the significantly higher urinary pH. That uric acid supersaturation fell somewhat more in patients with IH than those with Dent's disease during treatment with chlorthalidone is consistent with the fact that the baseline urinary pH in patients with IH (6.14) was lower than that in patients with Dent's disease (6.58) and thus closer to the pK for uric acid (5.5). The ClC-5 chloride channel that is inactivated by mutations in these patients is expressed in the ␣-intercalated cells of the collecting duct, although most patients with Dent's disease can acidify the urine normally when challenged (16, 17) . Our observation does not reflect abnormal buffer excretion, because excretion of ammonium and phosphate were similar in the two groups.
Phosphate excretion was slightly lower during all treatment periods, and this was significant for treatment with chlorthalidone. Since these patients should have been at steady state during these measurements, it seems unlikely that this would reflect diureticinduced changes in blood volume. It is possible that a small rise in serum calcium could have suppressed serum levels of PTH or 1,25-dihydroxyvitamin D, leading to a reduction in bone resorption or intestinal absorption of phosphate, but we cannot answer this question without measurements of serum levels.
Urinary calcium excretion was reduced to virtually identical degrees in the patients with Dent's disease and those with IH. This is not surprising, given that the ClC-5 chloride channel is not expressed in the thiazide-sensitive distal convoluted tubule (6) . Amiloride was ineffective either alone or in combination with chlorthalidone. This was not a consequence of ClC-5 inactivation, because it was as ineffective in patients with IH as in those with Dent's disease. Other reports on the effectiveness of amiloride on urinary calcium excretion in humans, using doses similar to those in this study, have described a reduction in calcium excretion in only a minority of calcium stone-formers (13), and only a modest a P Ͻ 0.05 a priori contrast comparing treatment with baseline, regardless of patient condition. b P Ͻ 0.01 a priori contrast comparing treatment with baseline, regardless of patient condition. c P Ͻ 0.05 a priori interaction contrast comparing treatment with baseline (i.e., Dent's patients' response to treatment relative to baseline is different from that of IH patients'.
d P Ͻ 0.05 main effect comparing patient types, regardless of treatment.
effect to augment the hypocalciuric effect of thiazides (14) . Costanzo and Weiner (18) have shown in dogs that the anticalciuretic effect of maximal doses of amiloride is much smaller than that of chlorothiazide, although the effects of the two diuretics are additive. In clinical practice, the major practical value of adding amiloride to a thiazide in a hypercalciuric stone-forming patient is to ameliorate hypokalemia. Even this effect, however, is not necessarily associated with a moderation of hypocitraturia, as demonstrated by Leppla et al. (13) and by our data (Table 3) . Despite the significant correction of hypercalciuria by chlorthalidone in both patient groups, the fall in supersaturation ratios for calcium oxalate was less impressive, primarily because of a generally lower mean citrate excretion. Nevertheless, in patients with Dent's disease, supersaturation ratio for calcium phosphate fell by 35% -despite a rise in urinary pH -and supersaturation ratio for calcium oxalate fell by 25%. Stones in patients with Dent's disease are composed of calcium oxalate, calcium phosphate, or a combination of the two (5, 16, 17) . Thiazides have been shown to reduce the rate of calcium stone recurrence in patients with IH (10,11), and we now show that the effects on urinary measures of stone risk are similar in patients with Dent's disease. Thus, it seems justified to treat hypercalciuric patients with Dent's disease with a thiazide diuretic if they have had recurrent stones. It is not clear whether hypercalciuria is the cause of renal failure in patients with Dent's disease, and thus we do not yet know whether therapy to reduce calcium excretion would be of any benefit in protecting renal function in these patients.
